Collaboration forms for development of kits to analyse biotherapeutic impurity

A licensing and supply agreement has been signed by Gyros Protein Technologies and Cygnus Technologies for the development of immunoassay kits for biotherapeutic impurity analysis.

Under the terms of the agreement, assay and services provider, Cygnus Technologies, will provide Gyros Protein Technologies with its proprietary reagents for host cell protein analysis, enabling the development of new Gyrolab immunoassay kits and applications to support customers working in biotherapeutics development and manufacturing.

Gyros Protein Technologies develops automated nanolitre-scale immunoassays and provides peptide synthesizers and reagents. Through its Gyrolab platforms and ready-to-use kits for CHO-HCP, protein A impurity analyses and IgG titre determinations, the company has established expertise in bioprocess development.

As a result of this new agreement, Gyros Protein Technologies’ customers will also benefit from products and expertise provided by Cygnus Technologies.

“The agreement with Cygnus Technologies forms part of our strategy to continue to support customers with high quality bioanalytical solutions, and to increase productivity in the development and manufacturing of biotherapeutics,” explained Dan Calvo, CEO and president, Gyros Protein Technologies. “Cygnus Technologies’ offering complements our current portfolio, and the partnership will enable us to increase our support to bioprocess customers.”

“This collaboration with Gyros Protein Technologies will give customers looking for automated solutions the opportunity to automate our well-characterised antibodies and antigens on the Gyrolab platforms,” stated Ken Hoffman, president of Cygnus Technologies. “Those same customers can also access custom antibody services along with state-of-the-art orthogonal analytical methods developed at Cygnus Technologies.”